0000000000224916

AUTHOR

Khalid Al Rasadi

showing 2 related works from this author

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

2022

The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for th…

LipoproteinsEndocrinology Diabetes and MetabolismDiabetes030209 endocrinology & metabolism030204 cardiovascular system & hematologyCardiovascular riskAtherosclerosisIncretinsBiochemistrySmall dense LDL3. Good health03 medical and health sciences0302 clinical medicineAtherosclerosis Cardiovascular risk Diabetes GLP-1 Incretins Lipoproteins Small dense LDL Therapylipids (amino acids peptides and proteins)TherapyGLP-1Molecular BiologyMetabolites
researchProduct

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes

2022

The current management of Type 2 Diabetes Mellitus (T2DM) includes incretin-based treatments able to enhance insulin secretion and peripheral insulin sensitivity as well as improve body mass, inflammation, plasma lipids, blood pressure, and cardiovascular outcomes. Dietary Free Fatty Acids (FFA) regulate metabolic and anti-inflammatory processes through their action on incretins. Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for T2DM. To comprehensively review the available evidence for the potential role of FFA receptor agonists in the treatment of T2DM, we performed an electronic database search assessing the association between FFAs, T2DM, i…

cardiovascular riskMedicine (General)Cardiovascular risk Free fatty acidsGLP-1 Incretins Metabolism Type 2 diabetes Fatty Acids Nonesterified Humans Diabetes Mellitus Type 2 Insulin Resistanceendocrine system diseasesfree fatty acidsType 2 diabetesReviewGeneral MedicineFatty Acids NonesterifiedR5-920Diabetes Mellitus Type 2HumansInsulin ResistanceGLP-1metabolismincretinsMedicina
researchProduct